1. Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study. Issue 5 (26th February 2018) Authors: Taylor, Peter C; Schiff, Michael H; Wang, Qingmin; Jiang, Yusang; Zhuang, Yanli; Kurrasch, Regina; Daga, Shruti; Rao, Ravi; Tak, Paul P; Hsu, Benjamin Journal: Annals of the rheumatic diseases Issue: Volume 77:Issue 5(2018) Page Start: 658 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Issue 10075 (25th March 2017) Authors: Aletaha, Daniel; Bingham, Clifton O; Tanaka, Yoshiya; Agarwal, Prasheen; Kurrasch, Regina; Tak, Paul P; Popik, Sharon Journal: Lancet Issue: Volume 389:Issue 10075(2017) Page Start: 1206 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0292 A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SIRUKUMAB IN THE TREATMENT OF PATIENTS WITH GIANT CELL ARTERITIS. (June 2019) Authors: Schmidt, Wolfgang; Dasgupta, Bhaskar; Luqmani, Raashid; Unizony, Sebastian; Lai, Zhihong; Kurrasch, Regina; Lazic, Ivana; Brown, Kurt; Rao, Ravi Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 827 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study. Issue 2 (16th November 2018) Authors: Thorne, Carter; Takeuchi, Tsutomu; Karpouzas, George Athanasios; Sheng, Shihong; Kurrasch, Regina; Fei, Kaiyin; Hsu, Benjamin Journal: RMD open Issue: Volume 4:Issue 2(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. Issue 2 (2nd July 2021) Authors: Tanaka, Yoshiya; Bae, Sang-Cheol; Bass, Damon; Curtis, Paula; Chu, Myron; DeRose, Kathleen; Ji, Beulah; Kurrasch, Regina; Lowe, Jenny; Meizlik, Paige; Roth, David A Journal: RMD open Issue: Volume 7:Issue 2(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Issue 12 (22nd August 2011) Authors: Taylor, Peter C; Quattrocchi, Emilia; Mallett, Stephen; Kurrasch, Regina; Petersen, Jørgen; Chang, David J Journal: Annals of the rheumatic diseases Issue: Volume 70:Issue 12(2011) Page Start: 2119 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years. Issue 1 (15th April 2022) Authors: Zhang, Fengchun; Zheng, Jie; Li, Yang; Wang, Guochun; Wang, Mingjun; Su, Yin; Gu, Jieruo; Li, Xingfu; Bass, Damon; Chu, Myron; Curtis, Paula; DeRose, Kathleen; Kurrasch, Regina; Lowe, Jenny; Meizlik, Paige; Roth, David A Journal: RMD open Issue: Volume 8:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗